Dysregulated pH in tumor microenvironment checkmates cancer therapy

BioImpacts

Volumn 3, Issue 4, 2013, Pages 149-162

  Barar, Jaleh ^a   Omidi, Yadollah ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Glycolysis; pH dysregulation; Tumor microenvironment Warburg effect

Indexed keywords

CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1; LACTIC ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; SODIUM PROTON EXCHANGE PROTEIN 1;

ACIDITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL PH; CELL TRANSPORT; CYTOPLASM; DRUG TARGETING; ENZYME RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR FLUID; EXTRACELLULAR MATRIX; GLYCOLYSIS; HUMAN; HYPOXIA; METASTASIS; NONHUMAN; PROTON TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TISSUE PRESSURE; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84893354269     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2013.036     Document Type: Review

References (95)

1. Omidi Y, Gumbleton M. Biological Membranes and Barriers. In: Mahato RI, editor. Biomaterials for Delivery and Targeting of Proteins Nucleic Acids. New York: CRC Press; 2005. p. 232-74.
2. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nat Immunol 2007; 8: 11-3.
3. Gray SG, Eriksson T, Ekstrom TJ. Methylation, gene expression and the chromatin connection in cancer (review). Int J Mol Med 1999; 4: 333-50.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
5. Reshkin SJ, Cardone RA, Harguindey S. Na+-H+ exchanger, pH regulation and cancer. Recent Pat Anticancer Drug Discov 2013; 8: 85-99.
6. Bellacosa A, Larue L. PI3K/AKT Pathway and the Epithelial-Mesenchymal Transition. In: Thomas-Tikhonenko A, editor. Cancer Genome and Tumor Microenvironment. New York: Springer Science; 2010. p. 11-32.
7. Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: Concepts and molecular links. Semin Cancer Biol 2012; 22: 396-403.
8. Kaihara T, Kusaka T, Nishi M, Kawamata H, Imura J, Kitajima K, et al. Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are closely related to liver metastasis. J Exp Clin Cancer Res 2003; 22: 117-23.
9. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-4.
10. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
11. Salem AF, Bonuccelli G, Bevilacqua G, Arafat H, Pestell RG, Sotgia F, et al. Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle 2011; 10: 3692-700.
12. Weber CE, Kuo PC. The tumor microenvironment. Surg Oncol 2012; 21: 172-7.
13. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 2003; 3: 615-22.
14. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891-9.
15. Martinez-Outschoorn UE, Balliet RM, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, et al. Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFkappaB activation in the tumor stroma. Cell Cycle 2012; 11: 4152-66.
16. Galluzzi L, Kepp O, Kroemer G. Reverse Warburg: straight to cancer. Cell Cycle 2012; 11: 1059.
17. Lopez-Lazaro M. The warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 2008; 8: 305-12.
18. Weljie AM, Jirik FR. Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. Int J Biochem Cell Biol 2011; 43: 981-9.
19. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
20. Gort EH, van Haaften G, Verlaan I, Groot AJ, Plasterk RH, Shvarts A, et al. The TWIST1 oncogene is a direct target of hypoxia-inducible factor-2alpha. Oncogene 2008; 27: 1501-10.
21. Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene 2008; 27: 684-93.
22. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003; 300: 241-6.
23. Temes E, Martin-Puig S, Acosta-Iborra B, Castellanos MC, Feijoo-Cuaresma M, Olmos G, et al. Activation of HIF-prolyl hydroxylases by R59949, an inhibitor of the diacylglycerol kinase. J Biol Chem 2005; 280: 24238-44.
24. Choi HJ, Eun JS, Kim BG, Kim SY, Jeon H, Soh Y. Vitexin, an HIF-1alpha inhibitor, has anti-metastatic potential in PC12 cells. Molecules and cells 2006; 22: 291-9.
25. Shin DH, Kim JH, Jung YJ, Kim KE, Jeong JM, Chun YS, et al. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading. Cancer Lett 2007; 255: 107-16.
26. Dikmen ZG, Gellert GC, Dogan P, Yoon H, Lee YB, Ahn CH, et al. In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem 2008; 104: 985-94.
27. Narita T, Yin S, Gelin CF, Moreno CS, Yepes M, Nicolaou KC, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res 2009; 15: 6128-36.
28. Choi D, Han J, Lee Y, Choi J, Han S, Hong S, et al. Caffeic acid phenethyl ester is a potent inhibitor of HIF prolyl hydroxylase: structural analysis and pharmacological implication. J Nutr Biochem 2010; 21: 809-17.
29. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL, et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008; 7: 90-100.
30. Lee K, Kim HM. A novel approach to cancer therapy using PX-478 as a HIF-1alpha inhibitor. Arch Pharm Res 2011; 34: 1583-5.
31. Shen Y, Wu Y, Chen M, Shen W, Huang S, Zhang L, et al. Effects of pantoprazole as a HIF-1alpha inhibitor on human gastric adenocarcinoma sgc-7901 cells. Neoplasma 2012; 59: 142-9.
32. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 2005; 46: 31-6.
33. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006; 66: 3197-204.
34. Herling A, Konig M, Bulik S, Holzhutter HG. Enzymatic features of the glucose metabolism in tumor cells. The FEBS journal 2011; 278: 2436-59.
35. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol 2012; 24: 650-4.
36. Chiarugi A, Dolle C, Felici R, Ziegler M. The NAD metabolome--a key determinant of cancer cell biology. Nat Rev Cancer 2012; 12: 741-52.
37. Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 2010; 285: 9780-91.
38. Drevs J, Loser R, Rattel B, Esser N. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 2003; 23: 4853-8.
39. Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009; 113: 3276-86.
40. Fuchs D, Rodriguez A, Eriksson S, Christofferson R, Sundberg C, Azarbayjani F. Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance. Int J Cancer 2010; 126: 2773-89.
41. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2: 227-42.
42. Poot M, Hosier S, Swisshelm K. Distinct patterns of mitochondrial changes precede induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in MCF7 breast cancer cells. Exp Cell Res 2002; 279: 128-40.
43. Yalowitz JA, Pankiewicz K, Patterson SE, Jayaram HN. Cytotoxicity and cellular differentiation activity of methylenebis(phosphonate) analogs of tiazofurin and mycophenolic acid adenine dinucleotide in human cancer cell lines. Cancer Lett 2002; 181: 31-8.
44. Cullen JJ, Hinkhouse MM, Grady M, Gaut AW, Liu J, Zhang YP, et al. Dicumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism. Cancer Res 2003; 63: 5513-20.
45. Ota H, Tokunaga E, Chang K, Hikasa M, Iijima K, Eto M, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006; 25: 176-85.
46. Ciolino HP, Bass SE, MacDonald CJ, Cheng RY, Yeh GC. Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer 2008; 122: 990-8.
47. Lara E, Mai A, Calvanese V, Altucci L, Lopez-Nieva P, Martinez-Chantar ML, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009; 28: 781-91.
48. Mahraoui L, Rousset M, Dussaulx E, Darmoul D, Zweibaum A, Brot-Laroche E. Expression and localization of GLUT-5 in Caco-2 cells, human small intestine, and colon. Am J Physiol 1992; 263: G312-8.
49. Rudlowski C, Moser M, Becker AJ, Rath W, Buttner R, Schroder W, et al. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 2004; 66: 404-10.
50. Rudlowski C, Becker AJ, Schroder W, Rath W, Buttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol 2003; 120: 691-8.
51. Ozerlat I. Kidney cancer: targeted therapy of glucose uptake via GLUT1 kills RCC cells. Nat Rev Urol 2011; 8: 471.
52. Shen YM, Arbman G, Olsson B, Sun XF. Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers 2011; 26: 166-72.
53. Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, et al. GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011; 26: 1279-86.
54. Anderson CM, Thwaites DT. Hijacking solute carriers for proton-coupled drug transport. Physiology 2010; 25: 364-77.
55. Verstraete M, Debucquoy A, Devos E, Sagaert X, Penninckx F, Begg A, et al. Investigation of possible endogenous hypoxia markers in colorectal cancer. Int J Radiat Biol 2013; 89: 9-15.
56. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, et al. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012; 11: 1108-17.
57. Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int 2012; 110: 1062-9.
58. Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY, et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 2011; 102: 1007-13.
59. Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, et al. The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 2009; 45: 2418-24.
60. Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, et al. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication. Blood 2008; 112: 2013-6.
61. Shen MR, Wilkins RJ, Chou CY, Ellory JC. Anion exchanger isoform 2 operates in parallel with Na(+)/H(+) exchanger isoform 1 during regulatory volume decrease of human cervical cancer cells. FEBS letters 2002; 512: 52-8.
62. Reshkin SJ, Bellizzi A, Cardone RA, Tommasino M, Casavola V, Paradiso A. Paclitaxel induces apoptosis via protein kinase A- and p38 mitogen-activated protein-dependent inhibition of the Na+/H+ exchanger (NHE) NHE isoform 1 in human breast cancer cells. Clin Cancer Res 2003; 9: 2366-73.
63. Beltran AR, Ramirez MA, Carraro-Lacroix LR, Hiraki Y, Reboucas NA, Malnic G. NHE1, NHE2, and NHE4 contribute to regulation of cell pH in T84 colon cancer cells. Pflugers Arch 2008; 455: 799-810.
64. Steffan JJ, Snider JL, Skalli O, Welbourne T, Cardelli JA. Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells. Traffic 2009; 10: 737-53.
65. Hosogi S, Miyazaki H, Nakajima KI, Ashihara E, Niisato N, Kusuzaki K, et al. An Inhibitor of Na/H(+) Exchanger (NHE), Ethyl-Isopropyl Amiloride (EIPA), Diminishes Proliferation of MKN28 Human Gastric Cancer Cells by Decreasing the Cytosolic Cl(-) Concentration via DIDS-Sensitive Pathways. Cell Physiol Biochem 2012; 30: 1241-53.
66. Salmon AJ, Williams ML, Wu QK, Morizzi J, Gregg D, Charman SA, et al. Metallocene-based inhibitors of cancer-associated carbonic anhydrase enzymes IX and XII. J Med Chem 2012; 55: 5506-17.
67. Smyth LG, O'Hurley G, O'Grady A, Fitzpatrick JM, Kay E, Watson RW. Carbonic anhydrase IX expression in prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 178-81.
68. Said HM, Supuran CT, Hageman C, Staab A, Polat B, Katzer A, et al. Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr Pharm Des 2010; 16: 3288-99.
69. Nakao M, Ishii G, Nagai K, Kawase A, Kenmotsu H, Kon-No H, et al. Prognostic significance of carbonic anhydrase IX expression by cancer-associated fibroblasts in lung adenocarcinoma. Cancer 2009; 115: 2732-43.
70. Pastorekova S, Kopacek J, Pastorek J. Carbonic anhydrase inhibitors and the management of cancer. Curr Top Med Chem 2007; 7: 865-78.
71. Zawacka-Pankau J, Grinkevich VV, Hunten S, Nikulenkov F, Gluch A, Li H, et al. Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem 2011; 286: 41600-15.
72. Gupta N, Martin PM, Prasad PD, Ganapathy V. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. Life sciences 2006; 78: 2419-25.
73. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin Invest 2008; 118: 3835-7.
74. Birsoy K, Wang T, Possemato R, Yilmaz OH, Koch CE, Chen WW, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nature genetics 2012; 45: 104-8.
75. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. Curr Pharm Des 2012; 18: 1345-71.
76. Loo SY, Chang MK, Chua CS, Kumar AP, Pervaiz S, Clement MV. NHE-1: a promising target for novel anti-cancer therapeutics. Curr Pharm Des 2012; 18: 1372-82.
77. Friday E, Oliver R, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: Relationship to mitochondrial membrane potential. J Cell Physiol 2011; 226: 511-9.
78. Wong P, Lee C, Tannock IF. Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res 2005; 11: 3553-7.
79. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Rey JM, Garcia-Garcia A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 2009; 35: 707-13.
80. von Schwarzenberg K, Lajtos T, Simon L, Muller R, Vereb G, Vollmar AM. V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. Mol Oncol 2013.
81. Baradaran B, Hosseini AZ, Majidi J, Farajnia S, Barar J, Saraf ZH, et al. Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice. Hum Antibodies 2009; 18: 11-6.
82. Rezaiemanesh A, Majidi J, Baradaran B, Movasaghpour A, Nakhlband A, Barar J, et al. Impacts of anti-EGFR monoclonal antibody in prostate cancer PC3 cells. Hum Antibodies 2010; 19: 63-70.
83. Tohidkia MR, Asadi F, Barar J, Omidi Y. Selection of potential therapeutic human single-chain Fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology. BioDrugs 2013; 27: 55-67.
84. Barkholt L, Bregni M. Current immunotherapy for solid tumors. Immunotherapy 2009; 1: 483-93.
85. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18: 81-100.
86. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nature reviews Cancer 2004; 4: 806-13.
87. Barar J, Omidi Y. Intrinsic bio-signature of gene delivery nanocarriers may impair gene therapy goals. Bioimpacts 2013; 3: 105-9.
88. Barar J, Hamzeiy H, Mortazavi-Tabatabaei SA, Hashemi-Aghdam SE, Omidi Y. Genomic signature and toxicogenomics comparison of polycationic gene delivery nanosystems in human alveolar epithelial A549 cells. Daru 2009; 17: 139-47.
89. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar S. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial a549 cells. Toxicol Mech Methods 2008; 18: 369-78.
90. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. JDrug Target 2007; 15: 83-8.
91. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology. Curr Drug Deliv 2005; 2: 429-41.
92. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target 2003; 11: 311-23.
93. Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in A431 cells. BioImpacts: BI 2011; 1: 23-30
94. Omidi Y, Barar J. Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int J Toxicol 2009; 28: 113-22.
95. Omidi Y, Davaran S. Impacts of biodegradable polymers: Towards biomedical applications. In: Sharma S, A Mudhoo, editors. Handbook of Applied Biopolymer Technology: Synthesis, Degradation and Applications. Cambridge: Royal Society of Chemistry; 2011. p. 388-418.